|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
�źŴ��� |
|
��� |
| ��������������� | |
|
������ |
|
֣���� |
| PubMed | |
|
Article by |
|
Article by |
��ϸ���ź�ת��;����صĿ���м��ҩ�����ðе�
������, ֣����
�й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о���, �Ͼ� 210042
�ź�;�����쳣�������ԺͷǶ�����ֳ�Լ�������Դ,�ɴ����������ź�ת�����ơ��ĸ���.����м��������������ϸ����ֳ�йص������������ź�Rasת��ͨ·��ϸ���������ź�JAKsSTATsת��;��������м����֢��ص�ϸ���ź�ת��;������صġ�DZ�ڵ�ҩ�����ðе���һ����.
[2] Ben-Bassat H.Biological activity of tyrosine kinase inhibitors:novel agents for psoriasis therapy.Curr Opin Investig Drugs,2001,2(11):1539-1545.
[3] Levitzki A.Protein tyrosine kinase inhibitors as novel therapeutic agents.Pharmacol Ther,1999,82(2-3);231-239.
[4] Traxler P,Furet P.Strategies toward the design of novel and selective protein tyrosine kinase inhibitors.Pharmacol Ther,1999,82(2-3):195-206.
[5] Levitzki A.Signal-transduction therapy.A novel approach to disease management.Eur J Biochem,1994,226(1);1-13.
[6] Jost M,Class R,Kari C,et al.A central role of Bcl-X(L)in the regulation of keratinocyte survival by autocrine EGFR ligands.J Invest Dermatol,1999,112(4);443-449.
[7] Cuzzocrea S,McDonald MC,Mazzon E,et al.The tyrosine kinase inhibitor tyrphostin AG126 reduces the development of acute and chronic inflammation.Am J Pathol,2000,157(1);145-158.
[8] Powell TJ,Ben-Bassat H,Klein BY,et al.Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors.Br J Dermatol,1999,141(5);802-810.
[9] Fong TA,Shawver LK,Sun L,et al.SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor(Flk-1/KDR)that inhibits tyrosine kinase catalysis,tumor vascularization,and growth of multiple tumor types.Cancer Res,1999,59(1);99-106.
[10] Dvorak HF,Brown LF,Detmar M,et al.Vascular permeability factor/vascular endothelial growth factor,microvascular hyperpermeability,and angiogenesis.Am J Pathol,1995,146(5);1029-1039.
[11] Hasan J,Jayson GC.VEGF antagonists.Expert Opin Biol Ther,2001,1(4);703-718.
[12] Bosco MC,Curiel RE,Zea AH,et al.IL-2 signaling in human monocytes involves the phosphorylation and activation of p59hck.J Immunol,2000,164(9);4575-4585.
[13] Kamens JS,Ratnofsky SE,Hirst GC.Lck inhibitors as a therapeutic approach to autoimmune disease and transplant rejection.Curt Opin Investig Drugs,2001,2(9):1213-1219.
[14] Lin P,Baldassare JJ,Voorhees JJ,et al.Increased activation of Ras in psoriatic lesions.Skin Pharmacol Appl Skin Physiol,1999,12(1-2);90-97.
[15] Hirano T.Interleukin 6 and its receptor:ten years later.Int Rev Immunol,1998,16(3-4);249-284.
[16] Jackson M,Howie SE,Weller R,et al.Psoriatic keratinocytes show reduced IRF-1 and STAT-1 alpha activation in response to gamma-IFN.FASEB J,1999,13(3);495-502.
[17] Lewis AJ,Manning AM.New targets for anti-inflammatory drugs.Curr Opin Chem Biol,1999,3(4);489-494.
[18] Haase I,Hobbs RM,Romero MR,et al.A role for mitogen-activated protein kinase activation by integrins in the pathogenesis of psoriasis.J Clin Invest,2001,108(4);527-536.
[19] Murdoch C,Finn A.Chemokine receptors and their role in inflammation and infectious diseases.Blood,2000,95(10);3032-3043.